Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FPR1 | P21462 | 4/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581609 | 1.00 | P2RX7 (0.61) | P2RX7HRH2HRH1ADORA1KMT2A | |
| SCHEMBL9994565 | 0.92 | P2RX7 (0.60) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL9994564 | 0.92 | P2RX7 (0.60) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL22303692 | 0.89 | P2RX7 (0.57) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL22338765 | 0.89 | P2RX7 (0.57) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL6767381 | 0.89 | FPR2 (0.59) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL5155529 | 0.89 | FPR2 (0.59) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL5151249 | 0.89 | FPR2 (0.59) | P2RX7HRH2HRH1KMT2AFPR1 | |
| SCHEMBL12618897 | 0.89 | P2RX7 (0.54) | P2RX7HRH2HRH1ADORA1KMT2A | |
| SCHEMBL10420634 | 0.88 | FPR2 (0.60) | P2RX7HRH2HRH1KMT2AFPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | P2RX7 14/4885HRH2 237/4885HRH1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.